Enzalutamide, sold under the brand name Xtandi, is a nonsteroidal antiandrogen medication used in the treatment of prostate cancer. It works by inhibiting androgen receptors, blocking the effects of testosterone and other androgens that stimulate the growth of prostate cancer cells. Enzalutamide is commonly prescribed for metastatic and non-metastatic castration-resistant prostate cancer (CRPC) and is often part of combination therapy.

Parent: Enzalutamide
Parent: Enzalutamide
Parent: Enzalutamide
Parent: Enzalutamide
Parent: Enzalutamide
Parent: Enzalutamide
Parent: Enzalutamide
Parent: Enzalutamide
Parent: Enzalutamide
Parent: Enzalutamide
Parent: Enzalutamide
Parent: Enzalutamide
Parent: Enzalutamide
Parent: Enzalutamide
Parent: Enzalutamide
Parent: Enzalutamide
Parent: Enzalutamide
Parent: Enzalutamide
Parent: Enzalutamide
Parent: Enzalutamide
Parent: Enzalutamide
During the production and storage of Enzalutamide, related compounds and impurities may form, which must be controlled to ensure the drug’s safety and efficacy. Regulatory authorities, such as the U.S. Food and Drug Administration (FDA), provide strict guidelines on permissible impurity levels in Enzalutamide formulations.
Key aspects of Enzalutamide-related compounds and impurities include:
Advanced analytical methods, such as High-Performance Liquid Chromatography (HPLC), are used to detect and quantify Enzalutamide-related compounds and impurities, ensuring compliance with stringent quality standards.
No, Enzalutamide is not a form of chemotherapy. It is a nonsteroidal antiandrogen medication that works by blocking androgen receptors, inhibiting the growth of prostate cancer cells. Unlike chemotherapy, it does not target rapidly dividing cells throughout the body.
Enzalutamide is used to treat metastatic and non-metastatic castration-resistant prostate cancer (CRPC). It is also prescribed for metastatic hormone-sensitive prostate cancer (mHSPC) as part of a combination therapy.
The success rate of Enzalutamide varies based on individual cases and stages of prostate cancer. Clinical trials have shown that it significantly delays disease progression and extends overall survival in patients with castration-resistant prostate cancer.
Both Abiraterone and Enzalutamide are used to treat prostate cancer but work differently. Abiraterone inhibits androgen production by blocking the enzyme CYP17A1, while Enzalutamide blocks androgen receptors directly, preventing androgens from stimulating cancer cell growth. The choice between the two depends on the patient’s condition and treatment goals.